5-Minute Journal Club — ASCO 2011 Presentations
Read All Issues CE Information and Faculty Disclosures
  • Overview
    This series of activities is comprised of abbreviated slide sets along with edited commentary from clinical investigators summarizing the significance of results presented at the ASCO 2011 Annual Meeting. Solid tumors that are highlighted include melanoma, GIST and breast, lung, ovarian, colorectal and genitourinary cancers. Hematologic cancers and related disorders that are highlighted include acute and chronic lymphoid and myeloid leukemias, myelodysplastic syndromes, myelofibrosis, multiple myeloma and diffuse large B-cell lymphoma.
  • Current Issue
    • Solid Tumors
    • Hematologic Cancers
    Read Dr Love’s original email (from September 7, 2011)

    BREAST CANCER Effects of the Addition of Bevacizumab or Iniparib to Standard Chemotherapy for Breast Cancer, Including Triple-Negative Disease, in the Neoadjuvant and Metastatic Settings O’Shaughnessy J et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). Proc ASCO 2011;Abstract 1007.

    Dr O'Shaughnessy Presentation Summary

    Bear HD et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Proc ASCO 2011;Abstract LBA1005.

    Gerber B et al. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44). Proc ASCO 2011;Abstract 1006.

    Drs Bear and Gerber Presentation Summaries

    Brufsky A et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. Proc ASCO 2011;Abstract 1010.

    Dr Brufsky Presentation Summary
     MELANOMA Response and Survival with Dacarbazine and Vemurafenib for the Treatment of BRAFV600E-Mutated Melanoma and Dacarbazine and Ipilimumab for the First-Line Treatment of Advanced-Stage Melanoma Chapman PB et al. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. Proc ASCO 2011;Abstract LBA4.

    Dr Chapman Presentation Summary

    Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26. Abstract

    Wolchok JD et al. Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. Proc ASCO 2011;Abstract LBA5.

    Drs Robert and Wolchok Presentation Summaries
     GIST Final Results of the SSGXVIII/AIO Study on the Treatment of Operable GIST with High Risk of Recurrence with 36 versus 12 Months of Adjuvant Imatinib Joensuu H et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). Proc ASCO 2011;Abstract LBA1.

    Dr Joensuu Presentation Summary     OVARIAN CANCER Efficacy and Safety of Bevacizumab Combined with Chemotherapy, Followed by Bevacizumab, in the Treatment of Newly Diagnosed and Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Aghajanian C et al. OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Proc ASCO 2011;Abstract LBA5007.

    Dr Aghajanian Presentation Summary

    Kristensen G et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Proc ASCO 2011;Abstract LBA5006.

    Dr Kristensen Presentation Summary     LUNG CANCER Studies in Advanced NSCLC of Maintenance Pemetrexed and Erlotinib and of BIBW 2992 or MetMAb Targeted Therapy for Acquired Resistance to Erlotinib and Gefitinib Janjigian YY et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. Proc ASCO 2011;Abstract 7525.

    Dr Janjigian Presentation Summary

    Spigel DR et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Proc ASCO 2011;Abstract 7505.

    Dr Spigel Presentation Summary

    Paz-Ares L et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). Proc ASCO 2011;Abstract CRA7510.

    Dr Paz-Ares Presentation Summary

    Rosell R et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib versus Chemotherapy (EURTAC) phase III randomized trial. Proc ASCO 2011;Abstract 7503.

    Dr Rosell Presentation Summary     PROSTATE CANCER Phase II Trial Results with Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer Hussain M et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. Proc ASCO 2011;Abstract 4516.

    Dr Hussain Presentation Summary     COLORECTAL CANCER Capecitabine–Based Chemoradiation Therapy in the Preoperative Treatment of Rectal Cancer Roh MS et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Proc ASCO 2011;Abstract 3503.

    Hofheinz R et al. Capecitabine (cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, Phase III trial. Proc ASCO 2011;Abstract 3504.

    Drs Roh and Hofheinz Presentation Summaries
    Read Dr Love’s original email (from September 19, 2011)

    MYELOFIBROSIS A Report on the Results of the COMFORT-I and COMFORT-II Trials of the JAK1/JAK2 Inhibitor Ruxolitinib for Myelofibrosis Verstovsek S et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Proc ASCO 2011;Abstract 6500.

    Dr Verstovsek Presentation Summary

    Harrison CN et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). Proc ASCO 2011;Abstract LBA6501.

    Dr Harrison Presentation Summary
     CHRONIC MYELOID LEUKEMIA First-Line Therapy for CML-CP with Nilotinib or Dasatinib Compared to Imatinib and the Incidence of Treatment-Emergent BCR-ABL Mutations in Patients Who Received Nilotinib or Imatinib for CML-CP in the ENESTnd Trial Saglio G et al. The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up. Proc ASCO 2011;Abstract 6502.

    Dr Saglio Presentation Summary

    Larson RA et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. Proc ASCO 2011;Abstract 6511.

    Kantarjian H et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the Phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12(9):841-51. Abstract

    Dr Larson Presentation Summary

    Kantarjian H et al. Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION. Proc ASCO 2011;Abstract 6510.

    Dr Kantarjian Presentation Summary     ACUTE LYMPHOCYTIC LEUKEMIA Activity of Inotuzumab Ozogamicin in Refractory/Relapsed Acute Lymphocytic Leukemia Jabbour E et al. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of > 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). Proc ASCO 2011;Abstract 6507.

    Dr Jabbour Presentation Summary     MULTIPLE MYELOMA Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM Palumbo AP et al. Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older. Proc ASCO 2011;Abstract 8007.

    Dr Palumbo Presentation Summary

    Rossi AC et al. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). Proc ASCO 2011;Abstract 8008.

    Dr Rossi Presentation Summary

    Dimopoulos MA et al. Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. Proc ASCO 2011;Abstract 8009.

    Dr Dimopoulos Presentation Summary

    Boccadoro M et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial. Proc ASCO 2011;Abstract 8020.

    Dr Boccadoro Presentation Summary     CHRONIC LYMPHOCYTIC LEUKEMIA Phase Ib/II Study of the Activity and Tolerability of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 in CLL/SLL Byrd JC et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. Proc ASCO 2011;Abstract 6508.

    Dr Byrd Presentation Summary     DIFFUSE LARGE B-CELL LYMPHOMA Reports from Phase III Trials of CHOP-Containing Regimens for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Cunningham D et al. R-CHOP14 versus R-CHOP21: Result of a randomized Phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell lymphoma. Proc ASCO 2011;Abstract 8000.

    Dr Cunningham Presentation Summary

    Stiff PJ et al. Randomized Phase III US/Canadian Intergroup trial (SWOG S9704) comparing CHOP±R x 8 vs CHOP±R x 6 followed by high dose therapy and auto transplant for patients with diffuse aggressive non-Hodgkin's lymphoma (NHL) in high-intermediate (H-Int) or high IPI risk groups. Proc ASCO 2011;Abstract 8001.

    Dr Stiff Presentation Summary     ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC SYNDROMES Clinical Trial Results with Novel Agents and Regimens for the Treatment of Newly Diagnosed or Relapsed/Refractory AML/MDS, Including in the Elderly Faderl S et al. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. Proc ASCO 2011;Abstract 6503.

    Dr Faderl Presentation Summary

    Thomas XG et al. Results from a randomized Phase 3 trial of decitabine vs supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. Proc ASCO 2011;Abstract 6504.

    Dr Thomas Presentation Summary

    Pollyea DA et al. Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: Completed results of the phase I study. Proc ASCO 2011;Abstract 6505.

    Dr Pollyea Presentation Summary

    Borthakur G et al. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. Proc ASCO 2011;Abstract 6506.

    Dr Borthakur Presentation Summary